 | • レポートコード：MRC2312MG03830 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、63ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の人工関節感染症治療市場規模と予測を収録しています。・世界の人工関節感染症治療市場：売上、2018年-2023年、2024年-2029年 ・世界の人工関節感染症治療市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の人工関節感染症治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「アミノグリコシド」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 人工関節感染症治療のグローバル主要企業は、Arrevus、 MELINTA THERAPEUTICS, INC.、 Nabriva Therapeutics plc、 Peptilogics、 Telephus Medical LLC、 TenNor Therapeutics Ltd、 Cempra Inc、 Motif Bio Plc、 Johnson & Johnson Servicesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、人工関節感染症治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の人工関節感染症治療市場：タイプ別、2018年-2023年、2024年-2029年 世界の人工関節感染症治療市場：タイプ別市場シェア、2022年 ・アミノグリコシド、糖ペプチド、リファマイシン、リンコサミド、ペニシリン、その他 世界の人工関節感染症治療市場：用途別、2018年-2023年、2024年-2029年 世界の人工関節感染症治療市場：用途別市場シェア、2022年 ・病院、診療所、その他 世界の人工関節感染症治療市場：地域・国別、2018年-2023年、2024年-2029年 世界の人工関節感染症治療市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における人工関節感染症治療のグローバル売上、2018年-2023年 ・主要企業における人工関節感染症治療のグローバル売上シェア、2022年 ・主要企業における人工関節感染症治療のグローバル販売量、2018年-2023年 ・主要企業における人工関節感染症治療のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Arrevus、 MELINTA THERAPEUTICS, INC.、 Nabriva Therapeutics plc、 Peptilogics、 Telephus Medical LLC、 TenNor Therapeutics Ltd、 Cempra Inc、 Motif Bio Plc、 Johnson & Johnson Services ************************************************************* ・調査・分析レポートの概要 人工関節感染症治療市場の定義 市場セグメント 世界の人工関節感染症治療市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の人工関節感染症治療市場規模 世界の人工関節感染症治療市場規模：2022年 VS 2029年 世界の人工関節感染症治療市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの人工関節感染症治療の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の人工関節感染症治療製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：アミノグリコシド、糖ペプチド、リファマイシン、リンコサミド、ペニシリン、その他 人工関節感染症治療のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、診療所、その他 人工関節感染症治療の用途別グローバル売上・予測 ・地域別市場分析 地域別人工関節感染症治療市場規模 2022年と2029年 地域別人工関節感染症治療売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Arrevus、 MELINTA THERAPEUTICS, INC.、 Nabriva Therapeutics plc、 Peptilogics、 Telephus Medical LLC、 TenNor Therapeutics Ltd、 Cempra Inc、 Motif Bio Plc、 Johnson & Johnson Services ... |
This research report provides a comprehensive analysis of the Artificial Joint Infection Treatment market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Artificial Joint Infection Treatment market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Artificial Joint Infection Treatment, challenges faced by the industry, and potential opportunities for market players.
The global Artificial Joint Infection Treatment market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Artificial Joint Infection Treatment market presents opportunities for various stakeholders, including Hospital, Clinic. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Artificial Joint Infection Treatment market. Additionally, the growing consumer demand present avenues for market expansion.
The global Artificial Joint Infection Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the Artificial Joint Infection Treatment market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Artificial Joint Infection Treatment market.
Market Overview: The report provides a comprehensive overview of the Artificial Joint Infection Treatment market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Aminoglycosides, Glycopeptides), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Artificial Joint Infection Treatment market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Artificial Joint Infection Treatment market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Artificial Joint Infection Treatment market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Artificial Joint Infection Treatment market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Artificial Joint Infection Treatment market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Artificial Joint Infection Treatment market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Artificial Joint Infection Treatment, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Artificial Joint Infection Treatment market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Artificial Joint Infection Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Aminoglycosides
Glycopeptides
Rifamycin
Lincosamide
Penicillin
Others
Market segment by Application
Hospital
Clinic
Others
Global Artificial Joint Infection Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Arrevus
MELINTA THERAPEUTICS, INC.
Nabriva Therapeutics plc
Peptilogics
Telephus Medical LLC
TenNor Therapeutics Ltd
Cempra Inc
Motif Bio Plc
Johnson & Johnson Services
Outline of Major Chapters:
Chapter 1: Introduces the definition of Artificial Joint Infection Treatment, market overview.
Chapter 2: Global Artificial Joint Infection Treatment market size in revenue.
Chapter 3: Detailed analysis of Artificial Joint Infection Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Artificial Joint Infection Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Artificial Joint Infection Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Artificial Joint Infection Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Artificial Joint Infection Treatment Overall Market Size
2.1 Global Artificial Joint Infection Treatment Market Size: 2022 VS 2029
2.2 Global Artificial Joint Infection Treatment Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Artificial Joint Infection Treatment Players in Global Market
3.2 Top Global Artificial Joint Infection Treatment Companies Ranked by Revenue
3.3 Global Artificial Joint Infection Treatment Revenue by Companies
3.4 Top 3 and Top 5 Artificial Joint Infection Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Artificial Joint Infection Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Artificial Joint Infection Treatment Players in Global Market
3.6.1 List of Global Tier 1 Artificial Joint Infection Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Artificial Joint Infection Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Artificial Joint Infection Treatment Market Size Markets, 2022 & 2029
4.1.2 Aminoglycosides
4.1.3 Glycopeptides
4.1.4 Rifamycin
4.1.5 Lincosamide
4.1.6 Penicillin
4.1.7 Others
4.2 By Type – Global Artificial Joint Infection Treatment Revenue & Forecasts
4.2.1 By Type – Global Artificial Joint Infection Treatment Revenue, 2018-2023
4.2.2 By Type – Global Artificial Joint Infection Treatment Revenue, 2024-2029
4.2.3 By Type – Global Artificial Joint Infection Treatment Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Artificial Joint Infection Treatment Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application – Global Artificial Joint Infection Treatment Revenue & Forecasts
5.2.1 By Application – Global Artificial Joint Infection Treatment Revenue, 2018-2023
5.2.2 By Application – Global Artificial Joint Infection Treatment Revenue, 2024-2029
5.2.3 By Application – Global Artificial Joint Infection Treatment Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Artificial Joint Infection Treatment Market Size, 2022 & 2029
6.2 By Region – Global Artificial Joint Infection Treatment Revenue & Forecasts
6.2.1 By Region – Global Artificial Joint Infection Treatment Revenue, 2018-2023
6.2.2 By Region – Global Artificial Joint Infection Treatment Revenue, 2024-2029
6.2.3 By Region – Global Artificial Joint Infection Treatment Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Artificial Joint Infection Treatment Revenue, 2018-2029
6.3.2 US Artificial Joint Infection Treatment Market Size, 2018-2029
6.3.3 Canada Artificial Joint Infection Treatment Market Size, 2018-2029
6.3.4 Mexico Artificial Joint Infection Treatment Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Artificial Joint Infection Treatment Revenue, 2018-2029
6.4.2 Germany Artificial Joint Infection Treatment Market Size, 2018-2029
6.4.3 France Artificial Joint Infection Treatment Market Size, 2018-2029
6.4.4 U.K. Artificial Joint Infection Treatment Market Size, 2018-2029
6.4.5 Italy Artificial Joint Infection Treatment Market Size, 2018-2029
6.4.6 Russia Artificial Joint Infection Treatment Market Size, 2018-2029
6.4.7 Nordic Countries Artificial Joint Infection Treatment Market Size, 2018-2029
6.4.8 Benelux Artificial Joint Infection Treatment Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Artificial Joint Infection Treatment Revenue, 2018-2029
6.5.2 China Artificial Joint Infection Treatment Market Size, 2018-2029
6.5.3 Japan Artificial Joint Infection Treatment Market Size, 2018-2029
6.5.4 South Korea Artificial Joint Infection Treatment Market Size, 2018-2029
6.5.5 Southeast Asia Artificial Joint Infection Treatment Market Size, 2018-2029
6.5.6 India Artificial Joint Infection Treatment Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Artificial Joint Infection Treatment Revenue, 2018-2029
6.6.2 Brazil Artificial Joint Infection Treatment Market Size, 2018-2029
6.6.3 Argentina Artificial Joint Infection Treatment Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Artificial Joint Infection Treatment Revenue, 2018-2029
6.7.2 Turkey Artificial Joint Infection Treatment Market Size, 2018-2029
6.7.3 Israel Artificial Joint Infection Treatment Market Size, 2018-2029
6.7.4 Saudi Arabia Artificial Joint Infection Treatment Market Size, 2018-2029
6.7.5 UAE Artificial Joint Infection Treatment Market Size, 2018-2029
7 Artificial Joint Infection Treatment Companies Profiles
7.1 Arrevus
7.1.1 Arrevus Company Summary
7.1.2 Arrevus Business Overview
7.1.3 Arrevus Artificial Joint Infection Treatment Major Product Offerings
7.1.4 Arrevus Artificial Joint Infection Treatment Revenue in Global Market (2018-2023)
7.1.5 Arrevus Key News & Latest Developments
7.2 MELINTA THERAPEUTICS, INC.
7.2.1 MELINTA THERAPEUTICS, INC. Company Summary
7.2.2 MELINTA THERAPEUTICS, INC. Business Overview
7.2.3 MELINTA THERAPEUTICS, INC. Artificial Joint Infection Treatment Major Product Offerings
7.2.4 MELINTA THERAPEUTICS, INC. Artificial Joint Infection Treatment Revenue in Global Market (2018-2023)
7.2.5 MELINTA THERAPEUTICS, INC. Key News & Latest Developments
7.3 Nabriva Therapeutics plc
7.3.1 Nabriva Therapeutics plc Company Summary
7.3.2 Nabriva Therapeutics plc Business Overview
7.3.3 Nabriva Therapeutics plc Artificial Joint Infection Treatment Major Product Offerings
7.3.4 Nabriva Therapeutics plc Artificial Joint Infection Treatment Revenue in Global Market (2018-2023)
7.3.5 Nabriva Therapeutics plc Key News & Latest Developments
7.4 Peptilogics
7.4.1 Peptilogics Company Summary
7.4.2 Peptilogics Business Overview
7.4.3 Peptilogics Artificial Joint Infection Treatment Major Product Offerings
7.4.4 Peptilogics Artificial Joint Infection Treatment Revenue in Global Market (2018-2023)
7.4.5 Peptilogics Key News & Latest Developments
7.5 Telephus Medical LLC
7.5.1 Telephus Medical LLC Company Summary
7.5.2 Telephus Medical LLC Business Overview
7.5.3 Telephus Medical LLC Artificial Joint Infection Treatment Major Product Offerings
7.5.4 Telephus Medical LLC Artificial Joint Infection Treatment Revenue in Global Market (2018-2023)
7.5.5 Telephus Medical LLC Key News & Latest Developments
7.6 TenNor Therapeutics Ltd
7.6.1 TenNor Therapeutics Ltd Company Summary
7.6.2 TenNor Therapeutics Ltd Business Overview
7.6.3 TenNor Therapeutics Ltd Artificial Joint Infection Treatment Major Product Offerings
7.6.4 TenNor Therapeutics Ltd Artificial Joint Infection Treatment Revenue in Global Market (2018-2023)
7.6.5 TenNor Therapeutics Ltd Key News & Latest Developments
7.7 Cempra Inc
7.7.1 Cempra Inc Company Summary
7.7.2 Cempra Inc Business Overview
7.7.3 Cempra Inc Artificial Joint Infection Treatment Major Product Offerings
7.7.4 Cempra Inc Artificial Joint Infection Treatment Revenue in Global Market (2018-2023)
7.7.5 Cempra Inc Key News & Latest Developments
7.8 Motif Bio Plc
7.8.1 Motif Bio Plc Company Summary
7.8.2 Motif Bio Plc Business Overview
7.8.3 Motif Bio Plc Artificial Joint Infection Treatment Major Product Offerings
7.8.4 Motif Bio Plc Artificial Joint Infection Treatment Revenue in Global Market (2018-2023)
7.8.5 Motif Bio Plc Key News & Latest Developments
7.9 Johnson & Johnson Services
7.9.1 Johnson & Johnson Services Company Summary
7.9.2 Johnson & Johnson Services Business Overview
7.9.3 Johnson & Johnson Services Artificial Joint Infection Treatment Major Product Offerings
7.9.4 Johnson & Johnson Services Artificial Joint Infection Treatment Revenue in Global Market (2018-2023)
7.9.5 Johnson & Johnson Services Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
